

September 2008

AG/Equine/2008-07pr

Equine Immunity, Vaccination Guidelines, and Recommendations

Dr. Kerry A. Rood, Extension Veterinarian, Utah State University Dr. Patricia A. Evans, Extension Equine Specialist, Utah State University

Why are horses vaccinated?

The ability to mount a defense against disease comes from a healthy immune system. Immunologists recognize that there are two basic forms of immunity, innate and active. Innate or passive immunity involves defensive immune responses that are passively acquired to combat disease. Most animals are born with several innate immune mechanisms and require additional immunity from ingestion of immunoglobulins (antibodies) from their mother's colostrum (first milk). Innate immunity is not specific for disease agents and therefore not very efficient. Yet passive immunity provides a critical step between birth and the gearing up of the active immune system.

Active immunity is more specific and generated from the animal's own immune system as the animal is exposed to pathogens (antigens). Because active immunity is developed in response or exposure to disease, the immunity is more specific, but requires more time to develop.

Animals are constantly exposed to disease pathogens. Vaccines are used as a tool to minimize the effect infectious diseases have on the animals through selectively manipulating the immune system. Vaccines have the ability to stimulate a more specific active immune response.

How do repeated doses or "boosters" affect immunity?

Boosters are required for most types of vaccines during the initial time given to fully stimulate the active immune system. These repeated doses (boosters) create an immune response that is longer in duration with a quicker response. The ability for an immune system to remember foreign pathogens and respond accordingly is called the animistic response. Foals require a series of boosters after the initial vaccine is given. As a foal's immune system matures, the first dose is often less effective when compared to subsequent boosters. It is critical to remember to administer the entire series of recommended shots in a given vaccine protocol.

Why do vaccinated horses have vaccine breakthroughs?

Vaccine breakthrough happens when animals get the disease even though they have been vaccinated. The primary culprit to this event is stress. Stress can affect the immune system in many different ways. In general, stress decreases the body's ability to mount or maintain an effective immunity. The biochemistry behind stress's negative effect on immunity is simply the over production of steroid (cortisol) in the body. This internal cortisol release may decrease the production and response of the immune system.

In the equine industry stress is most commonly found with weaning, training, traveling, and during gestation. Other times of stress can include the ambient temperature the horse is in. When seasons are drastic, and horses are exposed to hot and cold extremes, a horse's stress level may increase.

The vaccine recommendations vary from horse to horse depending on its stage of life and stress levels For example, the recommendation for equine influenza may increase if the horse is competing, yet decrease as the same horse is being rested for a season.

Another issue that can affect vaccine effectiveness is exposure. A vaccinated horse may come in contact with another horse that is shedding the disease. This increased exposure to the organism may be at levels which overwhelm the protective immunity of the vaccinated horse causing clinical signs. This can be a common cause of vaccine breakthrough.

Is following the label instructions important?

Each vaccine is packaged with label instructions. When administering any biological agent to a horse, one must first read the label and be familiar with stated precautions. Some vaccines contain warnings or precautions that should be followed to minimize the risk to horse and/or human. Vaccines should always be used prior to the expiration date and stored at the correct temperature indicated on the label. Vaccines are most effective when administered according to the label. If the route of administration is intramuscular, giving the injection just under the skin (subcutaneously) may not produce an equivalent immune response than the route indicated on the label.

Which diseases should I vaccinate my horse against?

A number of diseases can be prevented or the affect lessened through the use of vaccinations. While the purpose of this paper is to discuss vaccinations; management and biosecurity also play a critical role in the prevention of disease. Any good vaccination protocol should include thought and planning in management and biosecurity. Consideration should be given to your horse's exposure to common diseases. Horses that travel or are around other horses will have an increased exposure risk. It is critical to consult a veterinarian when developing a vaccination program as they can provide critical insight into the similarities and differences that one farm may have versus another.

Not all equine diseases are found throughout the United States or even throughout Utah. Therefore it is critical to discuss the common diseases seen in your area with a veterinarian. This conversation is essentially a risk assessment for equine diseases in the area. Those diseases recognized as common should be considered first when designing a vaccine strategy.

Vaccine Recommendationsⁱ

The American Association of Equine Practitioners (AAEP), made up of equine veterinarians throughout the world, has developed vaccination recommendations for many classes and stages of a horse's life and lifestyle. These recommendations identify the minimal core vaccine... Core vaccines are defined as vaccinations

> "that protect from diseases that are endemic to a region, those with potential public health significance, required by law, virulent/highly infectious, and/or those posing a risk of severe disease. Core vaccines have clearly demonstrated efficacy and safety, and thus exhibit a high enough level of patient benefit and low enough level of risk to justify their use in the majority of patients."ⁱⁱ

The attached guidelines list the core vaccines along with a variety of other potential vaccines. Again, a vaccination program must be fitted to each individual stable's situation (training facility, competing, boarding facility, etc.) and potential exposure to disease. Furthermore, horses in various life stages may require different vaccine considerations. The table is broken down into different life stages. Your veterinarian can assist in this evaluation. (Click on title to go directly to table.)

Vaccinations for Foals Vaccinations for Adult Horses

What are the core vaccines recommended for Utah?

Minimally, Utah horse owners should consider including tetanus, Eastern and Western equine encephalitis (EEE/WEE), and West Nile Virus (WNV) each year. The core vaccines could expand should the horse's travel expose it to other disease endemic areas, such as rabies. While Utah does not have reported cases of equine rabies, many neighboring states do (Colorado) and it is more common as you travel east.

Core vaccines for Utah:

- Tetanus
- Eastern and Western equine encephalitis (EEE/WEE)
- West Nile Virus (WNV)
- Rabies (for the public health aspect)

Which risk-based vaccines are commonly used in Utah?

Depending on stage of life, event activity and travel, the following risk-based vaccination regiment should be considered. Veterinarians also may recommend additional vaccines during gestation to help protect the fetus, along with increasing the quality of colostrum (mother's first milk).

Risk-based vaccines to consider are:

- Influenza
- Equine herpes virus (EHV)
- Strangles (if stable, show, or event requires; or if environmental risk is high)

Injection Sites

Vaccines have a specific route of administration indicated on their label. Common routes used are intramuscular (in the muscle), intranasal (in the nostril), and subcutaneous (SQ). The most common route is IM. There are several sites with quality muscle mass that are safe for vaccinations. Most vaccine type injections are given with a 20 gauge 1 to 1 ½ inch sterile needle and sterile syringe. Locations for injections (Figure 1) include the neck, pectorals, shoulder, lower hip, and thigh regions.



Figure 1. Areas of the horse used for IM injections.

Many people only give IM injections in the neck region but being aware of other sites is important. Some horses react to injections in the neck causing the neck to be sore. Some of these horses will not be able to put their heads down to eat or drink. Being able to give an injection in another site can make the horse more comfortable.

Many veterinarians will teach horse owners how to give injections. It is important to consult with your veterinarian before giving an injection.

Steps for giving an injection

- 1. Use sterile needles and syringes
- 2. Clean off site. This area does not need to be sterile but dirt should be brushed off.
- 3. Stand in a safe area so horse can't kick or bite you. Having a holder is important.
- 4. Remove the needle from the syringe. This helps the needle remain in the muscle if the horse moves away once the needle is inserted.
- 5. Bounce your hand or finger several times in the site.
- 6. Insert the needle perpendicular to the skin and full length of needle.
- 7. Attach the syringe and pull back on the plunger (aspirate). If blood is seen in the syringe upon aspirating, the needle should be redirected as IM substances are not meant to go into a blood vessel. To redirect, the needle can be backed out about one-half of its length and then directed back in on a different angle. Aspirate again.
- 8. Deposit the substance and remove the needle, dispose of the needle and syringe.

Summary

Vaccinations are an important part of horse management. Your horse can remain healthier when protected from diseases. Disease prevention is often less expensive than treatment or loss associated with disease. The American Association of Equine Practitioners (AAEP) has specific core and risk-based vaccine recommendations for your horse. Using these recommendations along with consultation with your local veterinarian can form the basis for a preventative health program specific for your area, needs, and horse.

Utah State University is committed to providing an environment free from harassment and other forms of illegal discrimination based on race, color, religion, sex, national origin, age (40 and older), disability, and veteran's status. USU's policy also prohibits discrimination on the basis of sexual orientation in employment and academic related practices and decisions.

Utah State University employees and students cannot, because of race, color, religion, sex, national origin, age, disability, or veteran's status, refuse to hire; discharge; promote; demote; terminate; discriminate in compensation; or discriminate regarding terms, privileges, or conditions of employment, against any person otherwise qualified. Employees and students also cannot discriminate in the classroom, residence halls, or in on/off campus, USUsponsored events and activities.

This publication is issued in furtherance of Cooperative Extension work, acts of May 8 and June 30, 1914, in cooperation with the U.S. Department of Agriculture, Noelle E. Cockett, Vice President for Extension and Agriculture, Utah State University.

¹ Adapted From American Association of Equine Practitioners (AAEP)

ⁱⁱ AVMA Policy Statement: *Vaccination Principles* (Approved by the AVMA Executive Board April 2001; revised April 2007).

VACCINATIONS FOR FOALS

<u>ALL</u> VACCINATION PROGRAMS SHOULD BE DEVELOPED IN CONSULTATION WITH A LICENSED VETERINARIAN

The two categories below reflect differences in the foal's susceptibility to disease and ability to mount an appropriate immune response to vaccination based on the presence (or absence) of maternal antibodies derived from colostrums. The phenomenon of maternal antibody interference is discussed in the text portion of these guidelines.

<u>CORE VACCINATIONS</u> protect against diseases that are endemic to a region, those with potential public health significance, required by law, virulent/highly infectious, and/or those posing a risk of severe disease. Core vaccines have clearly demonstrated efficacy and safety, and thus exhibit a high enough level of patient benefit and low enough level of risk to justify their use in all equids.

	Foals and Weanlings (<12 months of age)	Foals and Weanlings (<12 months of age)	
	Of mares vaccinated in the prepartum period against the disease indicated	Of unvaccinated mare	
DISEASE			COMMENTS
Tetanus	3-dose series: 1^{st} dose at 4-6 months of age 2^{nd} dose 4-6 weeks after the 1^{st} dose 3^{rd} dose at 10-12 months of age	3-dose series: 1^{st} dose at 1-4 months of age 2^{nd} dose at 4 weeks after the 1^{st} dose 3^{rd} dose 4 weeks after 2^{nd} dose	
Eastern/Western Equine Encephalomyelitis (EEE/WEE)	3-dose series: 1 st dose at 4-6 months of age* 2 nd dose at 4-6 weeks after 1 st dose 3 rd dose at 10-12 months of age, prior to the onset of the next vector season.	3-dose series: 1 st dose at 3-4 months of age* 2 nd dose 4 weeks after 1 st dose 3 rd dose at 10-12 months of age, prior to the onset of the next vector season.	<u>Note:</u> Primary vaccination series scheduling may be amended with vaccinations administered earlier to younger foals that are at increased disease risk due to the presence of vectors.
	* <i>Foals in the Southeastern USA:</i> The primary vaccination series should be initiated with an additional dose at 3 months of age due to early seasonal vector presence.	* <i>Foals in the Southeastern USA:</i> The primary vaccination series should be initiated at 3 months of age due to early seasonal vector presence.	A foal born during the vector season may warrant beginning vaccination at an earlier age than a foal born prior to the vector season.
Rabies	3-dose series: 1 st dose at 6 months of age 2 nd dose 4-6 weeks after 1 st dose 3 rd dose at 10-12 months of age	3-dose series: 1 st dose at 3-4 months of age 2 nd dose 4 weeks after 1 st dose 3 rd dose at 10-12 months of age	
West Nile Virus (WNV)	Inactivated vaccine* 3-dose series: 1 st dose at 4-6 months of age 2 nd dose 4-6 weeks after 1 st dose 3 rd dose at 10-12 months of age, prior to the onset of the next vector season. <u>Recombinant canary pox vaccine</u> 3-dose series: 1 st dose at 5-6 months of age 2 nd dose 4 weeks after 1 st dose 3 rd dose at 10-12 months of age, prior to the onset of the next vector season.	Inactivated vaccine* 3-dose series: 1 st dose at 3-4 months of age 2 nd dose at 4 weeks after 1 st dose 3 rd dose at 10-12 months of age, prior to the onset of the next vector season. <u>Recombinant canary pox vaccine</u> 3-dose series: 1 st dose at 5-6 months of age 2 nd dose at 4 weeks after 1 st dose 3 rd dose at 10-12 months of age, prior to the onset of the next vector season.	<u>Note:</u> Primary vaccination series scheduling may be amended with vaccinations administered to younger foals that are at increased risk of exposure due to the presence of vectors. A foal born during the vector season may warrant initiation of the primary vaccination series at an earlier age than a foal born prior to the vector season
	<u>Flavivirus chimera vaccine</u> 2-dose series: 1 st dose at 5-6 months of age 2 nd dose at 10-12 months of age,	<u><i>Flavivirus chimera vaccine</i></u> 2-dose series: 1 st dose at 5-6 months of age 2 nd dose at 10-12 months of age	There is no data for the use of the recombinant or chimera product in foals <5 months of age. If either product is administered to foals at

	prior to the onset of the next vector season.	prior to the onset of the next vector season.	<5 months of age, the recommended primary schedule
			should still be completed.
	*Foals in the Southeastern USA:	*Foals in the Southeastern USA:	-
	Due to early seasonal vector presence,	Due to early seasonal vector presence,	
1	the primary vaccination series should	the primary vaccination series should	
1	be initiated earlier with the addition of	be initiated at 3 months of age.	
	a dose at 3 months of age.		

<u>RISK-BASED VACCINATIONS</u> are those having applications which may vary between individuals, populations, and geographic regions. Risk assessment should be performed by, or in consultation with, a licensed veterinarian to identify which vaccines are appropriate for a given horse or population of horses. The listing of a vaccine here is not a recommendation for its inclusion into a vaccination program. Vaccine scheduling is provided for use after it has been determined which, if any, risk-based vaccines are indicated. Note: vaccines are listed in this table in alphabetical order not in order of priority for use.

DISEASE	Foals and Weanlings (<12 months of age)	Foals and Weanlings (<12 months of age)	COMMENTS
	Of mares vaccinated in the prepartum period against the disease indicated	Of unvaccinated mares	
Anthrax	Not applicable. As it is not recommended to vaccinate mares during pregnancy there will be no foals of mares vaccinated prepartum	No age specific guidelines are available for this vaccine. Manufacturer's recommendation is for primary series of 2 doses administered subcutaneously at a 2-3 week interval.	Antimicrobial drugs must <u>not</u> be given concurrently with this vaccine. Caution should be used during storage, handling and administration of this live bacterial product. Consult a physician immediately should accidental human exposure (via mucus membranes, conjunctiva or broken skin) occur.
Botulism	3-dose series: 1^{st} dose 2-3 months of age 2^{nd} dose 4 weeks after 1^{st} dose 3^{rd} dose 4 weeks after 2^{nd} dose	3-dose series: 1 st dose 1-3 months of age 2 nd dose 4 weeks after 1 st dose 3 rd dose 4 weeks after 2 nd dose	Maternal antibody does not interfere with vaccination; foals at high risk may be vaccinated as early as 2 weeks of age.
Equine Herpesvirus (EHV)	Inactivated or modified live vaccine 3-dose series: 1 st dose 4-6 months of age 2 nd dose 4-6 weeks after 1 st dose 3 rd dose at 10-12 months of age Revaccinate at 6-month intervals	<u>Inactivated or modified live vaccine</u> 3-dose series: 1 st dose of 4-6 months of age 2 nd dose 4-6 weeks after 1 st dose 3 rd dose at 10-12 months of age Revaccinate at 6-month intervals.	
Equine Viral Arteritis (EVA)	Colt (male) foals: Single dose at 6- 12 months of age (see comments)	Colt (male) foals: Single dose at 6-12 months of age (see comments)	Prior to initial vaccination, colt (male) foals should undergo serologic testing and be confirmed negative for antibodies to EAV. Testing should be performed shortly prior to, or preferably at, the time of vaccination.As foals can carry colostral derived antibodies to EAV for up to 6 months, testing and vaccination should <u>not</u> be performed prior to 6 months of age.

Equine Influenza	Inactivated vaccine	Inactivated vaccine	An increased risk of disease may
Equine Innucliza	3-dose series:	3-dose series:	warrant vaccination of younger
	1^{st} dose at 6 months of age	1^{st} dose at 6 months of age	foals. Because some maternal,
	2^{nd} dose 3-4 weeks after 1^{st} dose	2^{nd} dose at 3-4 weeks after 1^{st} dose	anti-influenza antibody is likely to
	3^{rd} dose at 10-12 months of age	3^{rd} dose at 10-12 months of age	be present, a complete series of
	5 dose at 10-12 months of age	5 dose at 10-12 months of age	primary vaccinations should be
	Madificat line and a inc	Madificat line and since	
	<u>Modified live vaccine</u> 2-dose series administered	<u>Modified live vaccine</u> 2-dose series administered intranasally:	given after 6 months of age.
	intranasally:	1 st dose at 6-7 months of age	
	1 st dose at 6-7 months of age	2 nd dose at 11-12 months of age	
	2 nd dose at 11-12 months of age		
		Revaccinate at 6-month intervals	
	Revaccinate at 6-month intervals		
Potomac Horse	2-dose series:	2-dose series:	If risk warrants, vaccine may be
Fever (PHF)	1 st dose at 5 months of age	1 st dose at 5 months of age	administered to younger foals.
	2 nd dose 3-4 weeks after 1 st dose	2 nd dose 3-4 weeks after 1 st dose	Subsequent doses are to be
			administered at 4-week intervals
			until 6 months of age.
Rotavirus	Not recommended in foals	Not recommended in foals	
Strangles	Killed vaccine	Killed vaccine	Vaccination is <u>not</u> recommended
Streptococcus equi	3-dose series:	3-dose series:	as a strategy in outbreak
	1 st dose at 4-6 months of age	1 st dose at 4-6 months of age	mitigation.
	2^{nd} dose 4-6 weeks after 1^{st} dose	2^{nd} dose 4-6 weeks after 1^{st} dose	
	3 rd dose 4-6 weeks after 2 nd dose	3 rd dose 4-6 weeks after 2 nd dose	If risk warrants, the modified live
			vaccine (MLV) may be safely
	Modified live vaccine	Modified live vaccine	administered to foals as young as
	3-dose series administered	3-dose series administered intranasally:	6 weeks of age. However, vaccine
	intranasally:	1 st dose at 6-9 months of age	efficacy in this age group has not
	1 st dose at 6-9 months of age	2^{nd} dose 3-4 weeks after 1^{st} dose	been adequately studied. If MLV
	2 nd dose 3-4 weeks after 1 st dose	3 rd dose at 11-12 months of age	is administered to younger foals, a
	3 rd dose at 11-12 months of age		3 rd dose of vaccine should then be
			administered 2-4 weeks prior to
			weaning.

Vaccinations for Foals developed by the American Association of Equine Practitioners Infectious Disease Committee, 2008.

Click here to return to page 2.

VACCINATIONS FOR ADULT HORSES

<u>ALL</u> VACCINATION PROGRAMS SHOULD BE DEVELOPED IN CONSULTATION WITH A LICENSED VETERINARIAN

<u>CORE VACCINATIONS</u> protect against diseases that are endemic to a region, are virulent/highly contagious, pose a risk of severe disease, those having potential public health significance, and/or are required by law. Core vaccines have clearly demonstrable efficacy and safety, with a high enough level of patient benefit and low enough level of risk to justify their use in all equids.

DISEASE Tetanus	Broodmares Broodmares Previously vaccinated Annual, 4-6 weeks pre-partum	Other Adult Horses (>1 year of age) Previously vaccinated against the disease indicated	Other Adult Horses (>1 year of age) Unvaccinated or Lacking vaccination history 2-dose series 2 nd dose 4-6 weeks after 1 st dose.	COMMENTS Booster at time of penetrating injury or prior to
	Previously unvaccinated or having unknown vaccination history: 2-dose series 2 nd dose 4-6 weeks after 1 st dose Revaccinate 4-6 weeks pre- partum		Annual revaccination	administered over 6 months previously.
Eastern/Western Equine Encephalomyelitis (EEE/WEE)	Previously vaccinated: Annual, 4-6 weeks pre-partum Previously unvaccinated or having unknown vaccination history: 2-dose series 2 nd dose 4 weeks after 1 st dose Revaccinate 4-6 weeks pre-partum	Annual – spring, prior to onset of vector season	2-dose series 2 nd dose 4-6 weeks after 1 st dose Revaccinate prior to the onset of the next vector season	Consider 6-month revaccination interval for: 1. Horses residing in endemic areas 2. Immunocompressed horses
West Nile Virus (WNV)	 Previously vaccinated: Annual, 4-6 weeks pre-partum Unvaccinated or lacking vaccination history: It is preferable to vaccinate naïve mares when open. In areas of high risk, initiate primary series as described for unvaccinated adult horses. 	Annual – spring, prior to onset of vector season	Inactivated vaccine: 2-dose series 2 nd dose 4-6 weeks after 1 st dose Revaccinate prior to the onset of the next vector season Recombinant canary pox vaccine: 2-dose series 2 nd dose 4-6 weeks after 1 st dose Revaccinate prior to the onset of the next vector season Flavivirus chimera vaccine: Single dose Revaccinate prior to onset of the next vector season	 When using the inactivated or the recombinant product, consider 6-month revaccination interval for: Horses residing in endemic areas Juvenile (<5 yrs of age) Geriatric horses (>15 yrs of age) Immunocompressed horses
Rabies	Annual, 4-6 weeks pre-partum OR Prior to breeding*	Annual	Single dose Annual revaccination	*Due to the relatively long duration of immunity, this vaccine may be given post- foaling but prior to breeding and thus reduce the number of vaccines given to a mare pre-partum

<u>RISK-BASED VACCINES</u> are selected for use based on risk assessment^{**} performed by, or in consultation with, a licensed veterinarian. Use of these vaccines may vary between individuals, populations, and/or geographic regions. Note: Vaccines are listed in this table in alphabetical order, not in order of priority for use.

**Refer to "Principles of Vaccination" in main document for criteria used in performing risk assessment.

	D			1
	Broodmares	Other Adult Horses	Other Adult Horses	
		(>1 year of age)	(>1 year of age)	
		Previously vaccinated	Unvaccinated	
		against the disease	or	
		indicated	Lacking vaccination history	
DISEASE		maicaiea		COMMENTS
Anthrax	Not recommended during	Annual	2-dose series	Do not administer
	gestation		2 nd dose 3-4 weeks after 1 st dose Annual revaccination	concurrently with antibiotics.
				Use caution during storage, handling and administration. Consult a physician immediately if human exposure to vaccine occurs by accidental injection, ingestion, or otherwise through the conjunctiva or
				broken skin.
Botulism	Previously vaccinated:			
	Annual, 4-6 weeks pre-partum Previously unvaccinated or	Annual	$\begin{array}{l} \mbox{3-dose series} \\ 2^{nd} \mbox{ dose 4 weeks after } 1^{st} \mbox{ dose } \\ 3^{rd} \mbox{ dose 4 weeks after } 2^{nd} \mbox{ dose } \end{array}$	
	having unknown vaccination			
	history:		Annual revaccination	
	3-dose series			
	1 st dose at 8 months gestation			
	2 nd dose 4 weeks after 1 st dose			
	3 rd dose 4 weeks after 2 nd dose			
Equine	3-dose series with product labeled	Annual (see comments)	3-dose series	Consider 6-month
Herpesvirus	for protection against EHV		2^{nd} dose 4-6 weeks after 1^{st}	revaccination interval for:
(EHV)	abortion.		dose	1. Horses less than 5
			3^{rd} dose at 4-6 weeks after 2^{rd}	years of age.
	Give at 5, 7 and 9 months of		dose	2. Horses on breeding
	gestation.			farms or in contact
				with pregnant mares.
				3. Performance or show
Equine Viral	Not recommended unless high	Annual	Single dose (see comments)	horses at high risk. Prior to initial vaccination ,
Arteritis (EVA)	risk.	Annual	Single dose (see comments)	intact males and any horses
Arterius (EVA)	11SK.	Stallions, teasers:		potentially intended for
		Vaccinate 2-4 weeks		export should undergo
		before breeding season.		serologic testing and be
		berore breeding season.		confirmed negative for
		Mares: Vaccinate when		antibodies to EAV. Testing
		open.		should be performed shortly
				prior to, or preferably at, the
				time of vaccination.

Influenza Pre	eviously vaccinated:	Horses with ongoing risk	Modified live vaccine:	
	nactivated vaccine: Semi-	of exposure: semi-annual	Single dose administered	
	nnual with one dose	of exposure. semi-annuar	intransally.	
	dministered 4-6 weeks pre-	Horses at low risk of	Revaccinate semi-annually to	
		exposure:		
1	artum		annually.	
	anary pox vector vaccine:	Annual		
	emi-annual with one dose		Inactivated vaccine: 3-dose series	
	dministered 4-6 weeks pre-		2 nd dose 4-6 weeks after 1 st dose	
pa	artum		3 rd dose 3-6 months after 2 nd	
			dose	
	eviously unvaccinated or		Revaccinate semi-annual to	
	ving unknown vaccination		annually.	
	tory:			
	nactivated vaccine: 3-dose		Canary pox vector vaccine: 2-	
	eries		dose series	
	2 nd dose 4-6 weeks after 1 st		2 nd dose 4-6 weeks after 1 st dose	
	dose		Revaccinate semi-annually	
	3 rd dose 4-6 weeks pre-partum			
	anary pox vector vaccine:			
	2-dose series			
	2 nd dose 4-6 weeks after 1 st			
	dose but no later than 4			
	weeks pre-partum			
Potomac Horse Pre	eviously vaccinated: Semi-	Semi-annual to annual	2-dose series	A revaccination interval of
	nual, with one dose given 4-6		2^{nd} dose 3-4 weeks after 1^{st} dose	3-4 months may be
	eks prepartum.		Semi-annual or annual booster	considered in endemic areas
	oks propurtum.		Senir annual of annual booster	when disease risk is high
Pre	eviously unvaccinated or			when disease fisk is high
	ving unknown vaccination			
	tory:			
	lose series			
	st dose 7-9 weeks prepartum			
	nd dose 4-6 weeks prepartum			
	lose series	Not applicable	Not applicable	
		Not applicable	Not applicable	
1	a^{st} dose at 8 months gestation a^{rd} and 3^{rd} dose at 4-week			
	ntervals thereafter	0 1 1	17'11 1 ' · · · · M	NT ' 1' ' A
	eviously vaccinated:	Semi-annual to annual	<u>Killed vaccine containing M-</u>	Vaccination is <u>not</u>
	<i>Tilled vaccine containing M-</i>		<u>protein:</u>	recommended as a strategy
	<i>rotein</i>): Semi-annual with one		2-3 dose series	in outbreak mitigation
	ose given 4-6 weeks pre-		2^{nd} dose 2-4 weeks after 1^{st} dose	
pa	artum		3 rd dose (where recommended	
			by manufacturer) 2-4 weeks	
	eviously unvaccinated or		after 2 nd dose	
	ving unknown vaccination		Revaccinate semi-annually	
	tory:			
	<i>Tilled vaccine containing <u>M-</u></i>		Modified live vaccine: 2-dose	
	rotein): 3-dose series		series administered intranasally	
	2 nd dose 2-4 weeks after 1 st		2 nd dose 3 weeks after 1 st dose	
	dose		Revaccinate semi-annually to	
1 J	3 rd dose 4-6 weeks prepartum		annually	

Vaccinations for Adult Horses developed by the American Association of Equine Practitioners Infectious Disease Committee, 2008.

Click here to return to page 2.